Carregant...
Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States
BACKGROUND: US HIV treatment guidelines recommend branded once-daily, one-pill efavirenz/emtricitabine/tenofovir as preferred first-line antiretroviral treatment (ART). With the anticipated approval of generic efavirenz in 2012 in the US, the cost of a once-daily, three-pill alternative (generic efa...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3664029/ https://ncbi.nlm.nih.gov/pubmed/23318310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/0003-4819-158-2-201301150-00002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|